Obesity trends and body mass index changes after starting antiretroviral treatment: The Swiss HIV cohort study

Open Forum Infectious Diseases

Volumn 1, Issue 2, 2014, Pages

  Hasse, Barbara ^a   Iff, Martin ^b   Ledergerber, Bruno ^a   Calmy, Alexandra ^c   Schmid, Patrick ^d   Hauser, Christoph ^e   Cavassini, Matthias ^f   Bernasconi, Enos ^g   Marzolini, Catia ^h   Tarr, Philip E ^b   Aubert, V ⁱ   Barth, J ⁱ   Battegay, M ⁱ   Bernasconi, E ⁱ   Boni J ⁱ   Bucher, H C ⁱ   Burton Jeangros, C ⁱ   Calmy, A ⁱ   Cavassini, M ⁱ   Egger, M ⁱ   Elzi, L ⁱ   Fehr, J ⁱ   Fellay, J ⁱ   Furrer, H ⁱ   Fux, C A ⁱ   Gorgievski, M ⁱ   Gunthard H ⁱ   Haerry, D ⁱ   Hasse, B ⁱ   Hirsch, H H ⁱ   Hosli I ⁱ   Kahlert, C ⁱ   Kaiser, L ⁱ   Keiser, O ⁱ   Klimkait, T ⁱ   Kouyos, R ⁱ   Kovari, H ⁱ   Ledergerber, B ⁱ   Martinetti, G ⁱ   Martinez de Tejada, B ⁱ   Metzner, K ⁱ   Muller N ⁱ   Nadal, D ⁱ   Pantaleo, G ⁱ   Rauch, A ⁱ   Regenass, S ⁱ   Rickenbach, M ⁱ   Rudin, C ⁱ   Schoni Affolter F ⁱ   Schmid, P ⁱ   Schultze, D ⁱ   Schupbach J ⁱ   Speck, R ⁱ   Staehelin, C ⁱ   Tarr, P ⁱ   Telenti, A ⁱ   Trkola, A ⁱ   Vernazza, P ⁱ   Weber, R ⁱ   Yerly, S ⁱ   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e UNIVERSITY OF BERN   (Switzerland)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^g REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ NONE

Author keywords

Antiretroviral therapy; Body mass index; HIV infection; Immunosuppression; Longitudinal study; Obesity

Indexed keywords

EMTRICITABINE; LAMIVUDINE;

ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; ETHNICITY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; SEXUAL ORIENTATION; SMOKING;

EID: 84969384618     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu040     Document Type: Article

References (39)

1. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22.
2. Reis JP, Loria CM, Lewis CE, et al. Association between duration of overall and abdominal obesity beginning in young adulthood and coronary artery calcification in middle age. JAMA 2013; 310:280-8.
3. Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration (BMI Mediated Effects). Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1.8 million participants. Lancet 2014; 383:970-83.
4. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71-82.
5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
6. Kotler DP, Rosenbaum K,Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:228-37.
7. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2002; 31:50-5.
8. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-31.
9. Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. HIV Med 2008; 9:142-50.
10. Brown TT, Chu H, Wang Z, et al. Longitudinal increases in waist circumference are associated with HIV-serostatus, independent of antiretroviral therapy. AIDS 2007; 21:1731-8.
11. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39:557-61.
12. Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr 2000; 23:81-8.
13. Crum-Cianflone N, Tejidor R, Medina S, et al. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS 2008; 22 (12):925-30.
14. Lewis CE, Jacobs DR Jr, McCreath H, et al.Weight gain continues in the 1990s: 10-year trends in weight and overweight from the CARDIA study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 2000; 151:1172-81.
15. Clarke P, O'Malley PM, Johnston LD, Schulenberg JE. Social disparities in BMI trajectories across adulthood by gender, race/ethnicity and lifetime socio-economic position: 1986-2004. Int J Epidemiol 2009; 38:499-509.
16. Falutz J. HIV infection, body composition changes and related metabolic complications: contributing factors and evolving management strategies. Curr Opin Clin Nutr Metab Care 2011; 14:255-60.
17. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307:491-7.
18. Schoeni-Affolter F, Ledergerber B, Rickenbach M, et al. Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 2010; 39:1179-89.
19. WHO Expert Consultation , et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363:157-63.
20. Tate T,Willig AL,Willig JH, et al. HIV infection and obesity: where did all the wasting go? Antivir Ther. 2012; 17:1281-9.
21. Maas JJ, Dukers N, Krol A, et al. Body mass index course in asymptomatic HIV-infected homosexual men and the predictive value of a decrease of body mass index for progression to AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:254-9.
22. Palenicek JP, Graham NM, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival. Multicenter AIDS Cohort Study Investigators. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:366-73.
23. Crum-Cianflone N, Roediger MP, Eberly L, et al. Increasing rates of obesity among HIV-infected persons during the HIV epidemic. PLoS One 2010; 5:e10106.
24. Hankinson AL, Daviglus ML, Bouchard C, et al. Maintaining a high physical activity level over 20 years and weight gain. JAMA 2010; 304:2603-10.
25. Rissanen A, Heliovaara M, Aromaa A. Overweight and anthropometric changes in adulthood: a prospective study of 17,000 Finns. Int J Obes 1988; 12:391-401.
26. Williamson DF, Kahn HS, Remington PL, Anda RF. The 10-year incidence of overweight and major weight gain in US adults. Arch Intern Med 1990; 150:665-72.
27. Boodram B, Plankey MW, Cox C, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in theWomen's Interagency HIV Study. AIDS Patient Care STDS 2009; 23:1009-16.
28. Swiss Health Survey 2012 of the Swiss Federal Office of Statistics. Available at: http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/01/ new/nip_detail.html?gnpID=2013-523. Accessed 10 February 2014.
29. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-82.
30. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95.
31. Lakey W, Yang LY, YancyW, et al. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses 2013; 29:435-40.
32. Flegal KM, Troiano RP, Pamuk ER, et al. The influence of smoking cessation on the prevalence of overweight in the United States. New Engl J Med 1995; 333:1165-70.
33. Shlay JC, Bartsch G, Peng G, et al. Long-term body composition and metabolic changes in antiretroviral naive persons randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J Acquir Immune Defic Syndr 2007; 44:506-17.
34. Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-18.
35. McComsey GA, Kitch D, Sax PE, et al. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. Clin Infect Dis 2011; 53:185-96.
36. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-5.
37. Grunfeld C, Saag M, Cofrancesco J Jr, et al. Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS 2010; 24:1717-26.
38. Tien PC, Cole SR,Williams CM, et al. Incidence of lipoatrophy and lipohypertrophy in the women's interagency HIV study. J Acquir Immune Defic Syndr 2003; 34:461-6.
39. Brown T, Wang Z, Chu H, et al. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men. J Acquir Immune Defic Syndr 2006; 43:356-62.